You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
BioNTech及辉瑞新型肺炎疫苗获得欧盟批准授权有条件上市许可
阿思达克 12-22 13:33
BioNTech(BNTX.US)及辉瑞(PFE.US)公布,获得欧盟批准授权其新型肺炎疫苗COMIRNATY、或称BNT162b2之有条件上市许可。BioNTech和辉瑞已准备在第一时间向27个欧盟成员国输送第一批疫苗。

公司此前宣布与欧盟委员会达成协议,将向欧盟成员国供应2亿剂疫苗,欧盟并可在2021年额外购买1亿剂疫苗。该疫苗目前已在全世界40多个国家或地区获得有条件上市许可授权、紧急使用授权或临时使用授权。

BioNTech联合创始人兼行政总裁Ugur Sahin表示,未来数日将向欧洲提供疫苗,将继续收集受试者接种後两年内的有效性和安全性数据,并针对潜在的病毒变异来进行疫苗测试。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account